More MS news articles for May 2001

E-Z-EM Introduces Varibar Contrast Media For Imaging Examination of the Swallowing Process

http://finance.individual.com/display_news.asp?doc_id=BW20010522BW2340&page=news

Tuesday May 22 10:02am
Source: BusinessWire

WESTBURY, N.Y.--(BW HealthWire)--May 22, 2001--E-Z-EM, Inc., (AMEX: EZM.A and EZM.B) today announced that it has introduced the first family of contrast formulations designed specifically for fluoroscopic examination of the swallowing process. These products, trade named Varibar(TM), provide consistent, repeatable radiographic results in modified swallowing studies.

Commenting on the announcement, Patrice Plourde, E-Z-EM's Global Product Manager - G.I. Contrast, said, "Varibar is the first family of contrast media developed specifically for swallowing studies. The market had a need for standardization of product and technique in these important procedures: Varibar can provide that, plus offer versatility, convenience and the flexibility to tailor examinations to the individual patient. The Varibar system provides a range of low-, medium- and high-viscosity barium suspensions needed to evaluate the patient's ability to swallow liquid and solid materials of differing viscosities and volumes.

"These products were developed in cooperation with speech-language pathologists at leading research universities," said Plourde. "Each Varibar contrast product has been carefully formulated to mimic real food in both texture and taste. This helps ensure normal chewing and salivation, and a natural swallowing action. All three Varibar contrasts - Varibar Nectar, Varibar Honey and Varibar Pudding - share unique low-coating characteristics that leave the esophagus stripped and clean. This facilitates accurate diagnosis and valid treatment of oropharyngeal dysphagia. And Varibar's 40% weight-to-volume density is ideal for both analog and digital videofluoroscopy systems." Varibar Nectar, is provided in unit dose, "shake and drink" containers while Varibar Honey and Pudding are supplied in multi-dose tubes.

Disorders of the swallowing mechanism can range from minimal difficulty swallowing food and liquids to inability to swallow without a great risk of aspiration. It is estimated that over 10 million Americans have some degree of swallowing disorder and this number is expected to increase substantially with the aging of the U.S. population. Swallowing dysfunction can result from a number of reasons, including neuromuscular disorders that include Alzheimer's disease, Parkinson's disease, stroke and Multiple Sclerosis, and other disorders including trauma, various malignancies and complications resulting from surgery.

E-Z-EM, the world's largest manufacturer of contrast agents for gastrointestinal radiology, has developed the only CT injector on the market that can help detect contrast extravasation, the PercuPump(R) with patented EDA(TM) technology. The Company's wholly owned subsidiary, AngioDynamics, manufactures a wide range of products, including angiographic, thrombolytic, vascular access, and drainage products, as well as stents and medical devices for angioplasty. Enteric Products, Inc., another subsidiary, develops, manufactures and markets tests for detection of the ulcer-causing bacterium Helicobacter pylori. For additional information, please contact Frank Kerrigon at 1-800-544-4624, ext. 325, (E-mail: fkerrigon@ezem.com) or visit our corporate web site at www.ezem.com.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, general market conditions, competition and pricing, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended March 3, 2001,as well as its Annual Report on Form 10-K for the year ended June 3, 2000, may affect the actual results achieved by the Company.

Contact: E-Z-EM, Inc.
  Patrice Plourde
  Global Product Manager - G.I. Contrast
  1-800-544-4624, ext. 300